冠昊生物(300238.SZ):原總經理張永明辭職 聘任王新志為公司總經理
格隆匯 6 月 30日丨冠昊生物(300238.SZ)公告,董事會於近日收到張永明遞交的辭職報告,張永明因工作調整原因申請辭去公司總經理職務。張永明的辭職報告自送達董事會之日起生效。辭職後,張永明將繼續擔任公司第五屆董事會董事長(法定代表人)、戰略委員會主任委員、薪酬與考核委員會委員職務。
公司於2020年6月30日召開第五屆董事會第三次會議,審議通過了《關於聘任公司總經理的議案》,董事會根據董事長提名及提名委員會審核意見,同意聘任王新志為公司總經理,任期自董事會審議通過之日起至第五屆董事會屆滿之日止。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.